NBC News, April 27, 2016. National Center for Health Research weighs in on behavioral training programs for children with ADHD.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
FDA Panel Votes Against Sarepta’s Drug for Duchenne Muscular Dystrophy
STAT, April 25, 2016. A federal advisory panel voted Monday that a drug from Sarepta Therapeutics was not effective for treating Duchenne muscular dystrophy, a rare and fatal muscle-wasting disease. About 13,000 children, mostly boys, are afflicted.
Read More »To Sway Drug Approval, Patient Advocates Turn up The Heat on the FDA
The Washington Post, April 23, 2016. Parents are desperate for a treatment for their sons with a rare disease, but if FDA approves a drug that isn’t proven to work, we are all at risk. FDA will meet to consider this dilemma on Monday, April 25.
Read More »How the House, Senate Diverge on Patient Safety in Cures Bills
American Health Line, April 19, 2016. Patient safety experts, including Dr. Diana Zuckerman, report that the the Senate’s version of the House-approved 21st Century Cures Act has been updated but still needs more changes.
Read More »Device Recalls Surge in Recent Years, Prompting Question: Why?
General Surgery News, April 12, 2016. The FDA approves or clears thousands of new medical devices each year. This highly complex process of review has garnered criticism in recent years. Dr. Diana Zuckerman weighs in on the lack of quality of clinical testing and the FDA approval process.
Read More »